DOCSLIB.ORG

Chlorpromazine Versus Placebo for Schizophrenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chlorpromazine Versus Placebo for Schizophrenia Bond University Research Repository Chlorpromazine versus placebo for schizophrenia Adams, Clive E.; Awad, George A.; Rathbone, John; Thornley, Ben; Soares-Weiser, Karla Published in: Cochrane Database of Systematic Reviews DOI: 10.1002/14651858.CD000284.pub3 Licence: Other Link to output in Bond University research repository. Recommended citation(APA): Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K. (2014). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, 2014(1), [000284]. https://doi.org/10.1002/14651858.CD000284.pub3 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator. Download date: 11 Oct 2021 Cochrane Database of Systematic Reviews Chlorpromazine versus placebo for schizophrenia (Review) Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD000284. DOI: 10.1002/14651858.CD000284.pub3. www.cochranelibrary.com Chlorpromazine versus placebo for schizophrenia (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 6 OBJECTIVES ..................................... 6 METHODS ...................................... 6 RESULTS....................................... 12 Figure1. ..................................... 13 Figure2. ..................................... 15 Figure3. ..................................... 16 DISCUSSION ..................................... 20 AUTHORS’CONCLUSIONS . 23 ACKNOWLEDGEMENTS . 24 REFERENCES ..................................... 24 CHARACTERISTICSOFSTUDIES . 46 DATAANDANALYSES. 149 Analysis 1.1. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 1 Death. 154 Analysis 1.2. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 2 Relapse. 155 Analysis 1.3. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 3 Global state: 1a. No overall improvement (psychiatrist-rated). 156 Analysis 1.4. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 4 Global state: 1b. No overall improvement(nurse-rated). 158 Analysis 1.5. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 5 Global state: 2. Average endpoint score -shortterm(CGI,highscore=worse). 159 Analysis 1.6. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 6 Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated). ............... 160 Analysis 1.7. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 7 Global state: 3b. Severity of illness, severely ill or worse - medium term (CGI 5+ points, nurse-rated)................. 161 Analysis 1.8. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 8 Leaving the study early. 162 Analysis 1.9. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 9 Mental state: 1. Improved - short term (BPRS,50%change). 164 Analysis 1.10. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 10 Mental state: 2. Average endpoint scores(BPRS,highscore=worse). 165 Analysis 1.11. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 11 Behaviour: 1. Deteriorated/ disturbed/un-cooperative.. 166 Analysis 1.12. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 12 Behaviour: 2. Unchanged. 167 Analysis 1.13. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 13 Behaviour: 3. Average endpoint scores(RRS,highscore=worse). 168 Analysis 1.14. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 14 Behaviour: 4. Average endpoint score - short term (PBRS, high score=good). 169 Analysis 1.15. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 15 Behaviour: 5. Average endpoint scores - medium term (Fergus Falls Behavioural rating scale). ............... 169 Analysis 1.16. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 16 Adverse effects: 1. Movement disorders. ................................... 170 Analysis 1.17. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 17 Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse). 173 Analysis 1.18. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 18 Adverse effects: 1. Central nervous system..................................... 174 Analysis 1.19. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 19 Adverse effects: 3. Blood, skin, liver, eyes...................................... 176 Chlorpromazine versus placebo for schizophrenia (Review) i Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 1.20. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 20 Adverse effects: 4. Other. 178 Analysis 1.21. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 21 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un-cooperative................. 182 Analysis 1.22. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 22 SUBGROUP ANALYSIS: 2. ACUTEvsCHRONIC. 183 Analysis 1.23. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 23 SUBGROUP ANALYSIS: 3. HIGHvsLOWDOSE. 186 Analysis 1.24. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 24 SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA. 188 Analysis 1.25. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 25 SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007. 192 Analysis 1.26. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 26 SENSITIVITY ANALYSIS: 1. RANDOMISATION.. 194 Analysis 1.27. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 27 SENSITIVITY ANALYSIS: 2. ASSUMPTIONSFORLOSTBINARYDATA. 196 ADDITIONALTABLES. 196 APPENDICES ..................................... 197 FEEDBACK...................................... 200 WHAT’SNEW..................................... 203 HISTORY....................................... 203 CONTRIBUTIONSOFAUTHORS . 204 DECLARATIONSOFINTEREST . 204 SOURCESOFSUPPORT . 205 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 205 INDEXTERMS .................................... 205 Chlorpromazine versus placebo for schizophrenia (Review) ii Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Chlorpromazine versus placebo for schizophrenia Clive E Adams1, George A Awad2, John Rathbone3, Ben Thornley4, Karla Soares-Weiser5 1Cochrane Schizophrenia Group, The University of Nottingham, Nottingham, UK. 2Department of Psychiatry, University of Toronto, Toronto, Canada. 3Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia. 4Marsh Gibbon, UK. 5Cochrane Editorial Unit, Cochrane, London, UK Contact address: Clive E Adams, Cochrane Schizophrenia Group, The University of Nottingham, Institute of Mental Health, Innovation Park, Triumph Road„ Nottingham, NG7 2TU, UK. [email protected]. Editorial group: Cochrane Schizophrenia Group. Publication status and date: Edited (no change to conclusions), published in Issue 11, 2015. Citation: Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD000284. DOI: 10.1002/14651858.CD000284.pub3. Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. Objectives To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. Search methods We searched the Cochrane Schizophrenia Group’s Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. Selection criteria We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non- affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care. Data collection and analysis We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50% of participants were lost to follow-up. Where continuous data were included, we analysed this data using mean difference (MD) with a 95% confidence interval. We used a fixed-effect model. Main results We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow-up (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No difference was found in relapse rates in the short, medium or long term over
Load more

Recommended publications
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Current Biological Treatments of Schizophrenia
    Schizophrenia Block Adapted from the American Society for Clinical Psychopharmacology Model Curriculum * Learning Objectives • Identify major target symptoms of schizophrenia treatment • Become familiar with conventional & atypical antipsychotic medications • Recognize major side effects of antipsychotic medications • Recognize unique features of clozapine & depot antipsychotics Outline • Background about Schizophrenia • Dopamine Hypothesis • Dopamine Pathways • Efficacy of Anti-psychotics • Treats agitation • Prevents relapse • Compliance, Medication dose & relapse • Overview of an Antipsychotic Medication Trial • Different Anti-psychotic medications • Side effects of the Anti-psychotics • Common-EPS, TD, anti-cholinergic, metabolic syndrome, • Rare but serious-NMS • Antipsychotic selection and treatment strategies algorithm Dopamine Hypothesis of Schizophrenia Dopamine Hypothesis • Psychotic symptoms can be induced by dopamine agonists* • cocaine, amphetamines cause psychosis • All anti-psychotics are dopamine antagonists • Normal subjects-10% dopamine receptors occupied at baseline** • Schizophrenic subjects-20% dopamine receptors occupied at baseline** **Laruelle M, Quart J Nuc Med 1998;42:211 * Major Dopamine Pathways 1. Nigrostriatal tract- (extrapyramidal pathway) substantia nigra to caudate nucleus & putamen of the basal ganglia 2. Mesolimbic tract - midbrain tegmentum to nucleus accumbens & adjacent limbic structures 3. Mesocortical tract - midbrain tegmentum to anterior cortical areas 4. Tuberoinfundibular tract - arcuate &
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Protecting Mental Health in the Age of Anxiety: the Context of Valium's Development, Synthesis, and Discovery in the United States, to 1963 Catherine (Cai) E
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2009 Protecting mental health in the Age of Anxiety: The context of Valium's development, synthesis, and discovery in the United States, to 1963 Catherine (cai) E. Guise-richardson Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the History Commons Recommended Citation Guise-richardson, Catherine (cai) E., "Protecting mental health in the Age of Anxiety: The onc text of Valium's development, synthesis, and discovery in the United States, to 1963" (2009). Graduate Theses and Dissertations. 10574. https://lib.dr.iastate.edu/etd/10574 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Protecting mental health in the Age of Anxiety: The context of Valium’s development, synthesis, and discovery in the United States, to 1963 by Catherine (Cai) Guise-Richardson A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: History of Technology and Science Program of Study Committee: Hamilton Cravens, Co-Major Professor Alan I Marcus, Co-Major Professor Amy Sue Bix Charles Dobbs David Wilson Iowa State University Ames, Iowa 2009 Copyright © Catherine (Cai) Guise-Richardson, 2009. All rights reserved. ii TABLE OF CONTENTS LIST OF TABLES iv ABSTRACT v CHAPTER 1.
    [Show full text]
  • LEGISLATIVE ASSEMBLY Question on Notice
    LEGISLATIVE ASSEMBLY Question On Notice Thursday, 15 February 2018 2560. Ms M. M Quirk to the Minister for Police; I refer to the commencement of operation of the Road Traffic Amendment Act 2016 in March 2017 which introduced compulsory blood or urine samples to be taken from drivers involved in serious crashes, and I ask: (a) since March 2017 how many such samples have been taken; (b) for what specific substances are those blood or urine samples tested; (c) what are the results of those tests to date; and (d) what percentage of drivers have been found to have ingested more than one substance capable of impairing driving skills? Answer (a) The compulsory taking of blood from all drivers involved in serious crashes commenced on 10 March 2017. Between 10 March 2017 and 22 February 2018 (inclusive) a total of 398 blood test samples have been collected under the provision of the Road Traffic Amendment Act 2016. There have been no urine tests collected. (b) Please see attached table for a list of substances in blood sample that are identifiable in ChemCentre toxicology analysis (Paper Number). (c) Of the 398 blood samples collected, 48 are pending results of ChemCentre analysis. Of the 350 analysed, 259 samples had a specific substance(s) detected and 91 samples had no specific substance detected. d) Of the 259 samples with specific substance(s) detected, 92% were found to have multiple substances (more than one). Detectable Substances in Blood Samples capable of identification by the ChemCentre WA. ACETALDEHYDE AMITRIPTYLINE/NORTRIPTYLINE
    [Show full text]
  • CHAPTER 2 LITERATURE REVIEWS 2.1 Risperidone
    CHAPTER 2 LITERATURE REVIEWS 2.1 Risperidone Risperidone (Risperdal®) is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1, 2-benzisoxazol- 3- yl)-1-piperidinyl] ethyl]-6,7,8,9-tetrahydro- 2-methyl-4H-pyrido [1,2-a]pyrimidin- 4-one. Its molecular formula is C23H27FN4O2 (Figure 1) and its molecular weight is 410.49 (Leysen et al., 1988). Figure 1. Structural formula of risperidone (Avenoso et al., 2000) Risperidone is a white to slightly beige powder. It is practically insoluble in water, freely soluble in methylene chloride, and soluble in methanol and 0.1 N HCl. Risperdal® tablets are available in 0.25 mg (dark yellow), 0.5 mg (red-brown), 1 mg (white), 2 mg (orange), 3 mg (yellow), and 4 mg (green) strengths. Tablets of 0.25, 0.5, 2, 3, and 4 mg also contain talc and titanium dioxide. Risperdal® is also available as a 1 mg/mL oral solution. The inactive ingredients for this solution are tartaric acid, benzoic acid, sodium hydroxide, and purified water (Janssen et al., 1988). 2.1.1 The mechanism of action of risperidone The mechanism of action of risperidone, as with other antipsychotic drugs, is unknown. However, In vitro studies have shown that risperidone acts primarily as a serotonin 5 (5-HT2) and dopamine (D2) antagonist. It binds with highest affinity to serotonergic receptors. Risperidone also binds to alpha-1 and alpha-2 adrenergic and histamine (H1) receptors, although with much less affinity. Dissociation from 5-HT2 and H1 receptors is slow; however, the drug rapidly dissociates from dopaminergic and alpha adrenergic receptors.
    [Show full text]
  • (ESI) for Integrative Biology. This Journal Is © the Royal Society of Chemistry 2017
    Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2017 Table 1 Enriched GO terms with p-value ≤ 0.05 corresponding to the over-expressed genes upon perturbation with the lung-toxic compounds. Terms with corrected p-value less than 0.001 are shown in bold. GO:0043067 regulation of programmed GO:0010941 regulation of cell death cell death GO:0042981 regulation of apoptosis GO:0010033 response to organic sub- stance GO:0043068 positive regulation of pro- GO:0010942 positive regulation of cell grammed cell death death GO:0006357 regulation of transcription GO:0043065 positive regulation of apop- from RNA polymerase II promoter tosis GO:0010035 response to inorganic sub- GO:0043066 negative regulation of stance apoptosis GO:0043069 negative regulation of pro- GO:0060548 negative regulation of cell death grammed cell death GO:0016044 membrane organization GO:0042592 homeostatic process GO:0010629 negative regulation of gene ex- GO:0001568 blood vessel development pression GO:0051172 negative regulation of nitrogen GO:0006468 protein amino acid phosphoryla- compound metabolic process tion GO:0070482 response to oxygen levels GO:0045892 negative regulation of transcrip- tion, DNA-dependent GO:0001944 vasculature development GO:0046907 intracellular transport GO:0008202 steroid metabolic process GO:0045934 negative regulation of nucle- obase, nucleoside, nucleotide and nucleic acid metabolic process GO:0006917 induction of apoptosis GO:0016481 negative regulation of transcrip- tion GO:0016125 sterol metabolic process GO:0012502 induction of programmed cell death GO:0001666 response to hypoxia GO:0051253 negative regulation of RNA metabolic process GO:0008203 cholesterol metabolic process GO:0010551 regulation of specific transcrip- tion from RNA polymerase II promoter 1 Table 2 Enriched GO terms with p-value ≤ 0.05 corresponding to the under-expressed genes upon perturbation with the lung-toxic compounds.
    [Show full text]